Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-727-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 28 February - 31 March 2006
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Well conducted and well described study in accordance with GLP and OECD Guideline 471 without any deviation
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- His+ for S. typhimurium
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- other: see table 7.6.1/1
- Metabolic activation:
- with and without
- Metabolic activation system:
- 10 % S9 mix; S9 fraction prepared from liver homogenates of Sprague-Dawley OFA male rats induced with Aroclor 1254 (500 mg/kg bw) by intraperitoneal route
- Test concentrations with justification for top dose:
- PRELIMINARY CYTOTOXICITY ASSAY
- With and without S9 mix: 50, 150, 500, 1500 and 5000 μg/plate in TA 1535, TA 1537, TA 98, TA 100 and TA 102 using plate-incorporation method.
MUTAGENICITY ASSAYS
- Experiment 1 (without S9 mix, plate-incorporation method): 50, 150, 500, 1500, 3000 and 5000 μg/plate (TA 1535); 15, 50, 150, 500, 1500 and 3000 μg/plate (TA 1537); 15, 50, 150, 500 and 1000 μg/plate (TA 98); 0.5, 1.5, 5, 15, 50 and 150 μg/plate (TA 100 and TA 102)
- Experiment 1 (with S9 mix, plate-incorporation method): 50, 150, 500, 1500 and 5000 μg/plate (TA 1535, TA 1537, TA 98 and TA 102); 1.5, 5, 15, 50 and 150 μg/plate (TA 100)
- Experiment 2 (without S9 mix, plate-incorporation method): 50, 150, 500, 1000 and 2000 μg/plate (TA 1535 and TA 1537); 15, 50, 150, 500 and 1000 μg/plate (TA 98); 1.5, 5, 15, 50 and 100 μg/plate (TA 100 and TA 102)
- Experiment 2 (with S9 mix, pre-incubation method): 50, 150, 500, 1500 and 5000 μg/plate (TA 1535, TA 1537, TA 98 and TA 102); 1.5, 5, 15, 50, 150, 500, 1500 and 5000 μg/plate (TA 100) - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: Sodium azide (1 µg/plate for TA 100 and TA 1535); 9-Aminoacridine (50 µg/plate for TA 1537); 2-Nitrofluorene (2 µg/plate for TA 98), Mitomycin C (0.125 µg/plate for TA 102)
- Remarks:
- without metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 2-anthramine: 2 and 1 µg/plate for without and with pre-incubation, respectively for TA 1537, TA 1535, TA 98 and TA 100; Benzo[a]pyrene: 2 µg/plate for without and with pre-incubation for TA 102
- Remarks:
- with metabolic activation
- Details on test system and experimental conditions:
- SOURCE OF TEST SYSTEM: All five strains were obtained from B.N. Ames, University of California, Berkeley, U.S.A.
METHOD OF APPLICATION: Plate incorporation and preincubation methods
DURATION:
- Pre-incubation period for 60 minutes at 37 °C
- Incubation period for plates: 48-72 h at 37 °C (preliminary cytotoxicity assay) 48 h at 37 °C (mutagenicity assay)
NUMBER OF REPLICATIONS:
- Preliminary cytotoxicity assay: 1 plate/dose
- Mutagenicity assays: 3 plates/dose
DETERMINATION OF CYTOTOXICITY:
- Method: Cytotoxicity was checked by microscopic examination of the background lawn of plates.
OTHERS:
- Sterility of the test item, media and S9 mix were tested.
- Reading of results: Colonies were counted using colony counter. The results were expressed as the mean number of mutants per plate and, for each concentration of the test product, the following ratio was established:
Mean number of revertants per plate in presence of the test item / Mean number of revertants per plate without the test item - Evaluation criteria:
- Criteria based on biological significance:
- Strains TA 1535 and TA 1537: A 3-fold increase in the number of revertants compared to the vehicle control, at any dose level and/or evidence of a dose relationship was considered as a positive result in the assay.
- Strains TA 98, TA 100 and TA102: A 2-fold increase in the number of revertants compared to the vehicle control, at any dose level and/or evidence of a dose relationship was considered as a positive result in the assay.
Criteria based on statistical significance:
- Data were analysed by means of Dunnett's method (Mahon et al, 1989) allowing the comparison of the mean value for each dose to the mean value for the corresponding solvent control.
Reproducibility:
- A positive result observed in a single assay that could not be reproduced in at least 2 independent assays could not be considered of biological significance.
- All these criteria are not absolute, but they, however, help in coming to a decision, which can be conclusive in the majority of the cases (Brusick, 1980).
Comparison to historical control data:
- In some borderline cases, an additional criterion to be considered is the comparison between the number of revertants induced by the test compound and the laboratory historical control data. Indeed, an increase in each individual value that is above the highest value of corresponding historical control data can help supporting a conclusion such as “equivocal” or “weak” mutagen. - Statistics:
- Data were analysed by means of Dunnett's method (Mahon et al, 1989) allowing the comparison of the mean value for each dose to the mean value for the corresponding solvent control.
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
Solubility: Test item was not soluble in distilled water but it was highly soluble in DMSO up to 50 mg/mL.
Precipitation:
Preliminary cytotoxicity assay:
- Slight precipitation of the test substance on the plates was observed at 5000 μg/plate in all five strains.
Mutagenicity assays:
- Experiment 1: Slight precipitation was observed at 150 μg/plate (TA 100 and TA 102, -S9), 1000 μg/plate (TA 98, -S9) and 3000 μg/plate (TA 1537, -S9).
- Experiment 2: No precipitation was observed at any of the doses tested in any of the strains.
COMPARISON WITH HISTORICAL CONTROL DATA:
- Historical control data of the solvent and positive controls of the year 2005 were used to compare the revertant frequencies.
ADDITIONAL INFORMATION ON CYTOTOXICITY:
Preliminary cytotoxicity assay:
Without S9 mix:
- In strain TA 1537, at the highest dose of 5000 µg/plate, the test item induced a slight toxicity characterized by a decrease in the number of revertants.
In strain TA 98, the test item was found toxic, characterized by a total absence of revertants at the doses of 1500 and 5000 µg/plate.
- Test item was strongly toxic in both strains TA 100 and TA 102, at the highest dose (5000 µg/plate) where total absence of growth was noted. A strong toxicity was observed at the doses of 150, 500 and 1500 µg/plate, where a strong to slight toxicity on the background lawn and a total absence of revertants were noted.
With S9 mix:
- Slight toxicity (TA 1537, TA 98 and TA 102) was observed at 5000 µg/plate. Slight toxicity on the background lawn at 5000 µg/plate and strong decrease in the number of revertants from 50 to 5000 µg/plate was observed in TA 100.
Mutagenicity assays: Statistically significant decreases in the number of revertants were observed during the first and the second assay, both with and without metabolic activation, in all strains, particularly at the highest tested doses.
Without S9 mix:
- Experiment 1: Slight to moderate toxicity as well as a strong decrease in the number of revertants were observed at the dose of 5000 µg/plate in TA 1535, of 3000 µg/plate in TA 1537, of 150 µg/plate in TA 100 and TA 102. Cytotoxicity was observed at 1000 µg/plate in TA98.
- Experiment 2: Slight to moderate toxicity as well as a strong decrease in the number of revertants was observed at the doses of 1000 and 2000 µg/plate in strains TA 1535 and TA 1537, at the highest dose of 1000 µg/plate in strain TA98, and at 100 µg/plate in strains TA 102 and TA 100
With S9 mix:
- Experiment 1: Cytotoxicity was observed at 5000 μg/plate in TA 102.
- Experiment 2: Cytotoxicity was observed at 150, 500, 1500 and 5000 μg/plate (TA 100) and 5000 μg/plate (TA 102).
OTHERS:
- Sterility test of test item, S9 mix and media: No contamination was observed. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative without metabolic activation
negative with metabolic activation
Under these test conditions, Chimexane NB is not mutagenic with and without metabolic activation in S. typhimurium strains TA 1535, TA 1537, TA 98, TA 100 and TA 102 according to the Annex VI of the Directive 67/548/EEC and the Regulation (EC) N° 1272-2008 (CLP). - Executive summary:
In a reverse gene mutation assay in bacteria, performed according to the OECD Guideline 471 and in compliance with GLP, strains of Salmonella typhimurium (TA 1535, TA 1537, TA 98, TA 100 and TA 102) was exposed to Chimexane NB at the following concentrations:
Preliminary cytotoxicity assay:
- With and without S9 mix: 50, 150, 500, 1500 and 5000 μg/plate in TA 1535, TA 1537, TA 98, TA 100 and TA 102 using plate-incorporation method.
Mutagenicity assays:
- Experiment 1 (without S9 mix, plate-incorporation method): 50, 150, 500, 1500, 3000 and 5000 μg/plate (TA 1535); 15, 50, 150, 500, 1500 and 3000 μg/plate (TA 1537); 15, 50, 150, 500 and 1000 μg/plate (TA 98); 0.5, 1.5, 5, 15, 50 and 150 μg/plate (TA 100 and TA 102)
- Experiment 1 (with S9 mix, plate-incorporation method): 50, 150, 500, 1500 and 5000 μg/plate (TA 1535, TA 1537, TA 98 and TA 102); 1.5, 5, 15, 50 and 150 μg/plate (TA 100)
- Experiment 2 (without S9 mix, plate-incorporation method): 50, 150, 500, 1000 and 2000 μg/plate (TA 1535 and TA 1537); 15, 50, 150, 500 and 1000 μg/plate (TA 98); 1.5, 5, 15, 50 and 100 μg/plate (TA 100 and TA 102)
- Experiment 2 (with S9 mix, pre-incubation method): 50, 150, 500, 1500 and 5000 μg/plate (TA 1535, TA 1537, TA 98 and TA 102); 1.5, 5, 15, 50, 150, 500, 1500 and 5000 μg/plate (TA 100)
Metabolic activation system used in this study was 10 % S9 mix. S9 fraction was prepared from liver homogenates of Sprague-Dawley OFA male rats induced with Aroclor 1254 (500 mg/kg bw) by intraperitoneal route. Vehicle and positive control groups were also included in this test.
In preliminary cytotoxicity assay, slight precipitation was observed in the plates at 5000 μg/plate in all five strains. Test substance induced toxicity at 150, 500, 1500 and 5000 μg/plate (TA 100 and TA 102, -S9), 5000 μg/plate (TA 1537, -S9; TA 1537, TA 98, TA 100 and TA 102, +S9). Statistically significant decreases in the number of revertants were observed during the first and the second assay, both with and without metabolic activation in all strains. The positive and vehicle controls induced the appropriate responses in the corresponding strains. Test item showed no substantial increases in revertant colony numbers over control count obtained with any of the tester strains at any concentrations either in the absence or presence of S9 mix.
Under these test conditions, Chimexane NB is not mutagenic with and without metabolic activation in S. typhimurium strains TA 1535, TA 1537, TA 98, TA 100 and TA 102 according to the Annex VI of the Directive 67/548/EEC and the Regulation (EC) N° 1272-2008 (CLP).
Reference
Table 7.6.1/2: Mean revertant frequencies
Strains |
Doses (µg/plate) |
Mean revertants per plate |
|||||||
Experiment 1 |
Experiment 2 |
||||||||
-S9 |
+S9# |
-S9 |
+S9## |
||||||
Mean |
R |
Mean |
R |
Mean |
R |
Mean |
R |
||
TA 1535 |
Solvent control |
13.5 |
- |
8.5 |
- |
10.7 |
- |
5.8 |
- |
50 |
20.7 |
1.5 |
12.3 |
1.4 |
11.3 |
1.1 |
10.3 |
1.8 |
|
150 |
19.0 |
1.4 |
10.0 |
1.2 |
7.0 |
0.7 |
7.0 |
1.2 |
|
500 |
15.0 |
1.1 |
7.7 |
0.9 |
3.7 |
0.3 |
5.3 |
0.9 |
|
1000 |
- |
- |
- |
- |
2.3* |
0.2 |
- |
- |
|
1500 |
7.0 |
0.5 |
5.3 |
0.6 |
- |
- |
1.7* |
0.3 |
|
2000 |
- |
- |
- |
- |
0.3* |
0 |
- |
- |
|
3000 |
2.0* |
0.1 |
- |
- |
- |
- |
- |
- |
|
5000 |
0.3* |
0 |
4.3 |
0.5 |
- |
- |
2.3 |
0.4 |
|
PC |
477.3* |
40.8 |
572* |
59 |
363.3* |
36.3 |
162.3* |
25.8 |
|
TA 1537 |
Solvent control |
5.0 |
- |
2.83 |
- |
2.8 |
- |
3.7 |
- |
15 |
2.7 |
0.5 |
- |
- |
- |
- |
- |
- |
|
50 |
2.0 |
0.4 |
3.3 |
1.16 |
2.7 |
1 |
4.7 |
1.3 |
|
150 |
2.7 |
0.5 |
5.0 |
1.76 |
3.3 |
1.2 |
5.0 |
1.4 |
|
500 |
3.0 |
0.6 |
2.7 |
0.95 |
2.3 |
0.8 |
2.5 |
0.7 |
|
1000 |
- |
- |
- |
- |
1.7 |
0.6 |
- |
- |
|
1500 |
2.7 |
0.5 |
2.7 |
0.95 |
- |
- |
2.7 |
0.7 |
|
2000 |
- |
- |
- |
- |
0.0* |
0 |
- |
- |
|
3000 |
1.0 |
0.2 |
- |
- |
- |
- |
- |
- |
|
5000 |
- |
- |
3.7 |
1.31 |
- |
- |
1.3 |
0.4 |
|
PC |
418.3 |
126.8 |
361.3* |
84 |
452.0* |
150.7 |
111.0* |
22.2 |
|
TA 98 |
Solvent control |
18.2 |
- |
20.2 |
- |
18.3 |
- |
16.8 |
- |
15 |
15.7 |
0.9 |
- |
- |
16.7 |
0.9 |
- |
- |
|
50 |
13.3 |
0.7 |
24.7 |
1.2 |
15.0 |
0.8 |
16.7 |
1 |
|
150 |
13.7 |
0.8 |
20.7 |
1 |
9.7 |
0.5 |
21.0 |
1.3 |
|
500 |
11.3 |
0.6 |
29.0 |
1.4 |
6.7 |
0.4 |
14.7 |
0.9 |
|
1000 |
9.3 |
0.5 |
- |
- |
5.0* |
0.3 |
- |
- |
|
1500 |
- |
- |
21.0 |
1 |
- |
- |
21.7 |
1.3 |
|
5000 |
- |
- |
24.0 |
1.2 |
- |
- |
19.0 |
1.1 |
|
PC |
1101.3* |
60.2 |
2698.7* |
118.9 |
711.3* |
35.6 |
1354.7* |
81.1 |
|
TA 100 |
Solvent control |
115.2 |
- |
95.0 |
- |
110.3 |
- |
88.8 |
- |
0.5 |
111.0 |
1 |
- |
- |
- |
- |
- |
- |
|
1.5 |
118.0 |
1 |
105.7 |
1.1 |
81.3 |
0.7 |
108.7 |
1.2 |
|
5 |
107.0 |
0.9 |
107.0 |
1.1 |
90.3 |
0.8 |
96.7 |
1.1 |
|
15 |
113.3 |
1 |
91.7 |
1 |
77.0 |
0.7 |
93.3 |
1.1 |
|
50 |
87.7 |
0.8 |
109.0 |
1.1 |
64.0* |
0.6 |
94.0 |
1.1 |
|
100 |
- |
- |
- |
- |
22.3* |
0.2 |
- |
- |
|
150 |
48.7* |
0.4 |
101.3 |
1.1 |
- |
- |
84.3 |
0.9 |
|
500 |
- |
- |
- |
- |
- |
- |
49.7* |
0.6 |
|
1500 |
- |
- |
- |
- |
- |
- |
0.0 |
0 |
|
5000 |
- |
- |
- |
- |
- |
- |
0.0 |
0 |
|
PC |
625.3* |
4.9 |
3904* |
44.4 |
412.0* |
3.1 |
858.7* |
10.3 |
|
TA 102 |
Solvent control |
182.5 |
- |
257.0 |
- |
223.7 |
- |
271.5 |
- |
0.5 |
221.3 |
1.2 |
- |
- |
- |
- |
- |
- |
|
1.5 |
263.0* |
1.4 |
- |
- |
197.3 |
0.9 |
- |
- |
|
5 |
226.3 |
1.2 |
- |
- |
198.0 |
0.9 |
- |
- |
|
15 |
189.3 |
1 |
- |
- |
209.7 |
0.9 |
- |
- |
|
50 |
222.7 |
1.2 |
304.7 |
1.2 |
174.7 |
0.8 |
258.7 |
1 |
|
100 |
- |
- |
- |
- |
79.3* |
0.4 |
- |
- |
|
150 |
118.3* |
0.6 |
279.7 |
1.1 |
- |
- |
283.3 |
1 |
|
500 |
- |
- |
281.0 |
1.1 |
- |
- |
238.7 |
0.9 |
|
1500 |
- |
- |
261.3 |
1 |
- |
- |
259.0 |
1 |
|
5000 |
- |
- |
216.3 |
0.8 |
- |
- |
179.3* |
0.7 |
|
PC |
1525.7* |
6 |
1082.7* |
4.2 |
1468.3* |
6.4 |
1517.0* |
5.9 |
#:without pre-incubation; ##: with pre-incubation; R: ratio = number of mutants in the treated / number of mutants in the control; *: p<0.01 (Dunnett's t)
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
In a reverse gene mutation assay in bacteria, performed according to the OECD guideline 471, in compliance with GLP, CHIMEXANE NB was found to be non mutagenic in S. typhimurium TA 100, TA 98, TA 1535, TA 1537 and TA 102 with and without metabolic activation.
In an in vitro mammalian cell gene mutation test conducted with L5178Y mouse lymphoma cells according to OECD guideline 476 and in compliance with GLP, CHIMEXANE NB did not induce mutation at the tk locus of L5178Y mouse lymphoma cells in the absence and presence of a rat liver metabolic activation system.
Chimexane NB did not induce chromosomal aberrations in cultured human lymphocytes with and without metabolic activation when tested up to its limit of toxicity (according to OECD guideline 473 ). It was therefore not considered as clastogenic or aneugenic in cultured human lymphocytes.
After a single administration of 2000 mg/kg, concentrations of Chimexane NB measured in plasmas from Sprague-Dawley rats ranged from 863 to 1136 ng/mL and from 633 to 1305 ng/mL at 1 and 4-hour sampling time, respectively in males and from 1100 to 2237 ng/mL and from 1002 to 1356 ng/mL at 1 and 4-hour sampling time, respectively in females, clearly demonstrating the systemic exposure to Chimexane NB. Under the conditions of this assay, CHIMEXANE NB was evaluated as negative in the rat oral bone marrow micronucleus test at 2000 mg/kg/day for 2 consecutive days (according to OECD guideline 474).
Justification for classification or non-classification
As Chimexane NB was found negative in an in vitro reverse gene mutation assay in bacteria, an in vitro chromosome aberration test, in an in vitro mammalian cell gene mutation test and in an in vivo micronucleus test, it is therefore not classified as mutagenic according to Annex VI to the Directive 67/548/EEC and in CLP Regulation (EC) N° (1272-2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.